Stoke Therapeutics (STOK) Stock Price, News & Analysis

Company Overview

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy. In addition to STK-001, Stoke is advancing STK-002, its preclinical candidate for spinocerebellar ataxia type 6 (SCA6), along with other discovery-stage programs targeting genetic diseases characterized by insufficient protein levels. Stoke’s approach aims to address the underlying genetic deficiency rather than solely treating symptoms, positioning its pipeline to potentially benefit a range of patient populations with high unmet medical needs.

Since going public on the Nasdaq exchange in early 2020, Stoke Therapeutics has grown its research capabilities and established strategic collaborations to support its development efforts. The company’s leadership team brings together expertise in molecular biology, neurology and clinical development, guiding Stoke’s mission to translate its TANGO platform into transformative therapies. Stoke serves patient communities and clinical partners globally, with ongoing and planned trials conducted across North America and Europe.

Key Stats

• Today's Range: $31.62 to $32.85
• 50-Day Range: $27.68 to $33.02
• 52-Week Range: $12.86 to $40.22
• Volume: 866,578 shs
• Average Volume: 754,621 shs
• Market Capitalization: $2.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Moderate Buy

Stoke Therapeutics Stock Analysis - MarketRank™

Stoke Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 551st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Stoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Stoke Therapeutics has a consensus price target of $43.00, representing about 31.5% upside from its current price of $32.71.

Amount of Analyst Coverage

Stoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stoke Therapeutics are expected to grow in the coming year, from ($3.50) to ($3.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stoke Therapeutics is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stoke Therapeutics is -9.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stoke Therapeutics has a P/B Ratio of 6.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.87% of the float of Stoke Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Stoke Therapeutics has a short interest ratio ("days to cover") of 20.73, which indicates bearish sentiment.

Change versus previous month

Short interest in Stoke Therapeutics has recently increased by 12.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stoke Therapeutics does not currently pay a dividend.

Dividend Growth

Stoke Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.03

News Sentiment

Stoke Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 42 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for STOK on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $306,919.00 in company stock.

Percentage Held by Insiders

9.60% of the stock of Stoke Therapeutics is held by insiders.

Percentage Held by Institutions

Stoke Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 8/09/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:STOK
• CIK: 1623526
• Web: www.stoketherapeutics.com
• Phone: (781) 430-8200
• Fax: N/A
• Employees: 100
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Stoke Therapeutics: $43.00
• High Price Target: $60.00
• Low Price Target: $25.00
• Potential Upside/Downside: +31.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.89 million
• Net Margins: -753.60%
• Pretax Margin: -758.23%
• Return on Equity: -59.36%
• Return on Assets: -51.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.69
• Quick Ratio: 8.99

Sales & Book Value

• Annual Sales: $27.59 million
• Price / Sales: 76.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.36 per share
• Price / Book: 6.10

Miscellaneous

• Outstanding Shares: 64,526,000
• Free Float: 58,332,000
• Market Cap: $2.11 billion
• Optionable: Optionable
• Beta: 1.20